Cash In, Lawsuits Out: POET Technologies’ Recovery Runs on $430 Million and a New ETF

POET Technologies gains $430M cash cushion after Marvell termination; stock recovers 50% fueled by leveraged ETF and $5M production order. Q1 earnings report looms.

A $375 million financing spree has handed POET Technologies a cash cushion of roughly $430 million, but it arrives at a moment when the company needs every dollar to patch the hole left by a terminated partnership. The optical chip maker lost its customer Marvell Semiconductor—along with orders tied to the Celestial AI program—after Marvell alleged a breach of confidentiality in a letter dated April 23. The stock cratered 49% on April 27. Since then, the shares have staged an improbable recovery, climbing 50% the following week and touching nearly $13.90 on May 11.

The bounce has been turbocharged by a new financial product. Defiance ETFs launched the Defiance Daily Target 2X Long POET ETF in May, a leveraged vehicle that amplifies daily moves in the stock by two times. The fund does nothing for POET’s underlying business, but it has added fuel to the trading fire. On May 8 alone, the stock jumped 14.3% to $10.95 on volume of 71.3 million shares—a level of activity that would have been unthinkable before the crash.

Traders are latching onto a genuine operational milestone: a production order worth more than $5 million for POET’s Infinity Optical Engines. CEO Dr. Suresh Venkatesan has committed to delivering over 30,000 units this year, a target that now stands without the support of the cancelled Marvell business. The company insists it will hit that goal, a claim that will face its first serious test when first-quarter results are published later this month.

Analysts expect a net loss of $0.04 per share on revenue of roughly $250,000 for the first quarter. While that loss is narrower than the $0.11 per share deficit recorded in the third quarter of 2025, the revenue figure remains microscopic for a company with a market capitalization of $1.67 billion. The negative price-to-earnings ratio of roughly -19.60 underlines that the market is pricing in future growth, not current earnings.

That growth story is further complicated by a legal overhang. Multiple class-action lawsuits have been filed or hinted at since the Marvell fallout, though the stock’s rally has largely ignored the litigation risk. POET also faces a shareholder vote on relocating its corporate domicile to the United States, a move that would trigger PFIC classification and require the company to supply QEF data to U.S. investors.

For now, the company’s balance sheet buys time. More than $225 million in financing flowed in during the fourth quarter of 2025, followed by another $150 million in January 2026. Those funds account for the bulk of the $430 million in cash that POET reported at year-end 2025. The cash pile gives management runway to scale production, but it does not replace the recurring revenue that investors ultimately demand.

All eyes will be on the upcoming quarterly report to see whether the Marvell decision is addressed explicitly and whether the 30,000-unit target still looks achievable. Until then, POET shares are being driven as much by mechanics—the new 2x ETF, the momentum from the recovery, the sheer volatility—as by the operational story. The two forces are tightly intertwined, and neither is likely to loosen its grip anytime soon.